👤 Jing-Ming Li

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
3991
Articles
2551
Name variants
Also published as: Xiaofeng Li, Jingwen Li, Jiajia Li, Zhaolun Li, Litao Li, Ruyi Li, Xiaocun Li, Wanxin Li, Jianyu Li, Jinsong Li, Xinzhi Li, Guanqiao Li, Ying-Lan Li, Zequn Li, Yulin Li, Shaojian Li, Guang-Xi Li, Yubo Li, Bugao Li, Mohan Li, Yan-Xue Li, Qingchao Li, Xikun Li, Guobin Li, Hong-Tao Li, Enhong Li, Xiangnan Li, Yong-Jun Li, Hang Li, Xihao Li, Ziming Li, Rongqing Li, Chang-Da Li, Meng-Yue Li, Yuanchang Li, DaZhuang Li, Yicun Li, Xiao-Lin Li, Jiajie Li, Zhao-Yang Li, Shunqin Li, K-L Li, Xinjia Li, Yaqiong Li, Bin Li, Yuan-hao Li, Jianhai Li, Peiwu Li, Youran Li, Yongmei Li, Changyu Li, Ran Li, Peilin Li, X Y Li, Chunshan Li, Yixiang Li, Ming Zhou Li, Z Li, Ye Li, Guanglve Li, Zili Li, Xinmei Li, Yihao Li, Liling Li, Qing Run Li, Wulan Li, Meng-Yang Li, Ziyun Li, Haoxian Li, Xiaozhao Li, Jun-Ying Li, Da-Lei Li, Xinhai Li, Yongjiang Li, Wanru Li, Jinming Li, Huihui Li, Wenhao Li, Qiankun Li, Kailong Li, Shengxu Li, Shisheng Li, Sai Li, Guangwen Li, Hua Li, Xiuli Li, Dongmei Li, Yulong Li, Ru-Hao Li, Lanzhou Li, Zhi-Peng Li, Tingsong Li, Binjun Li, Chen Li, Jiayang Li, Yawei Li, Zunjiang Li, Chao Bo Li, Minglong Li, Donghua Li, Siming Li, Wenzhe Li, Fengli Li, Song Li, Zihan Li, Hsin-Hua Li, Jin-Long Li, Hongxin Li, You Li, Dongfeng Li, Xueyang Li, Xuelin Li, Fa-Hui Li, Caiyu Li, Zhen-Yuan Li, Guangpu Li, Teng Li, Wen-Jie Li, Ang Li, Hegen Li, Zhizong Li, Lu-Yun Li, Peng Li, Bao Li, Shiyu Li, Yin Li, Cai-Hong Li, Fang Li, Jiuke Li, Miyang Li, Chen-Xi Li, Mingxu Li, Panlong Li, Dejun Li, Changwei Li, Biyu Li, Yufeng Li, Miaoxin Li, Yaoqi Li, San-Feng Li, Hu Li, Bei Li, Sha Li, W H Li, Jiaming Li, Jiyuan Li, Ya-Qiang Li, Rongkai Li, Yani Li, Xiushen Li, Xiaoqing Li, Jinlin Li, Linke Li, Shuaicheng Li, C Y Li, Thomas Li, Siting Li, Xuebiao Li, Yingyi Li, Yongnan Li, Maolin Li, Jiyang Li, Jinchen Li, Jin-Ping Li, Zhongxuan Li, Xuewen Li, R Li, Xianlong Li, Aixin Li, Linting Li, Zhong-Xin Li, Xuening Li, Enhao Li, Guang Li, Xiaoming Li, Shengliang Li, Yongli Li, Z-H Li, Hujie Li, Baohong Li, Yue-Ming Li, Shuyuan Li, Zhaohan Li, L Li, Yuanmei Li, Alexander Li, Yanwu Li, Wen-juan Li, Hualing Li, Sibing Li, Qinghe Li, Xining Li, Pilong Li, Yun-Peng Li, Zonghua Li, C X Li, Huanan Li, Jingya Li, Liqin Li, Youjun Li, Zheng-Dao Li, Miao X Li, Zhenshu Li, KeZhong Li, Heng-Zhen Li, Linying Li, Chu-Qiao Li, Fa-Hong Li, Changzheng Li, Yuhui Li, Wei Li, Wen-Ying Li, Yaokun Li, Shuanglong Li, Zhi-Gang Li, Yufan Li, Liangqian Li, Guanghui Li, Xiongfeng Li, Fei-feng Li, Letai Li, Kangli Li, Ming Li, Runwen Li, Wenbo Li, Yarong Li, Side Li, Timmy Li, S E Li, Weidong Li, Xin-Tao Li, Ruotong Li, Xiuzhen Li, Shuguang Li, Chuan-Hai Li, Lingxi Li, Qiuya Li, Jiezhen Li, Haitao Li, Tingting Li, Guanghua Li, Yufen Li, Qin Li, Zhongyu Li, Deyu Li, Zhen-Yu Li, Hansen Li, Annie Li, Wenge Li, Jinzhi Li, Xueren Li, Chun-Mei Li, Yijing Li, Kaifeng Li, Wen-Xing Li, Meng-Yao Li, Chung-I Li, Zhi-Bin Li, Qintong Li, Xiao Li, Junping Li, PeiQi Li, Xiaobing Li, Naishi Li, Liangdong Li, Xin-Ping Li, Yan Li, Han-Ni Li, Pan Li, Shengchao A Li, Jiaying Li, Jun-Jie Li, Ruonan Li, Cui-lan Li, Shuhao Li, Huiqiong Li, Ruitong Li, Guigang Li, Lucia M Li, Chunzhu Li, Suyan Li, Chengquan Li, Zexu Li, Gen-Lin Li, Dianjie Li, Zhilei Li, Junhui Li, Tiantian Li, Xue Cheng Li, Ya-Jun Li, Wenyong Li, Ding-Biao Li, Desen Li, Tianjun Li, Yansong Li, Xiying Li, Weiyong Li, Zihao Li, Xinyang Li, Fadi Li, Huawei Li, Yu-quan Li, Cui Li, Xiaoyong Li, Y L Li, Xueyi Li, Jingxiang Li, Wenxue Li, Jihua Li, Jingping Li, Zhiquan Li, Zeyu Li, Yingpu Li, Jianglin Li, Yan-Hua Li, Jing-Yao Li, Zongdi Li, Ming V Li, Shawn Shun-Cheng Li, Aowen Li, Xiao-Min Li, Ya-Ting Li, Wan Jie Li, L K Li, Aimin Li, Dongbiao Li, Tiehua Li, Keguo Li, Yuanfei Li, Longhui Li, Jing-Yi Li, Zhonghua Li, Guohong Li, Chunyi Li, Botao Li, Peiyun Li, Xiuqi Li, L-Y Li, Qinglan Li, Zhenhua Li, Zhengda Li, Haotong Li, Yue-Ting Li, Luhan Li, Da Li, Yuancong Li, Yuxiu Li, Tian Li, YiPing Li, Beibei Li, Haipeng Li, Demin Li, Chuan Li, Ze-An Li, Changhong Li, Jianmin Li, Yu Li, Minhui Li, Yvonne Li, Yiwei Li, Zhichao Li, Jiayuan Li, Xiangzhe Li, Minglun Li, Siguang Li, Yige Li, Chengqian Li, Weiye Li, Xue-Min Li, Kenneth Kai Wang Li, Dong-fei Li, Xiangchun Li, Chiyang Li, Chunlan Li, Hulun Li, Juan-Juan Li, Hailong Li, Hua-Zhong Li, Kun-Peng Li, Jiaomei Li, Haijun Li, Jing Li, Xiangyun Li, Si Li, Ji-Feng Li, Yingshuo Li, Wanqian Li, Baixing Li, Zijing Li, Dengke Li, Yuchuan Li, Wentao Li, Qingling Li, Rui-Han Li, Xuhong Li, Dong Li, Hongyun Li, Zhonggen Li, Xiong Li, Penghui Li, Xiaoxia Li, Dezhi Li, Huiting Li, Xiaolong Li, Linqing Li, Jiawei Li, Sheng-Jie Li, Defa Li, Ying-Qing Li, X L Li, Yuyan Li, Kawah Li, Xin-Jian Li, Guangxi Li, Yanhui Li, Zhenfei Li, Shupeng Li, Sha-Sha Li, Gang Li, Panyuan Li, Ziyu Li, Mengxuan Li, Hong-Wen Li, Zhuo Li, Han-Wei Li, Xiaojuan Li, Weina Li, Xiao-Hui Li, Huaiyuan Li, Dongnan Li, Rui-Fang Li, Jianzhong Li, Huaping Li, Ji-Liang Li, C H Li, Bohua Li, Bing Li, Pei-Ying Li, Huihuang Li, Shaobin Li, Yunmin Li, Yanying Li, Ronald Li, Gui Lin Li, Chenrui Li, Shi-Hong Li, Shilun Li, Xinyu Li, John Zhong Li, Lujiao Li, Song-Chao Li, Chenghong Li, Dengfeng Li, Nianfu Li, Baohua Li, N Li, Xiaotong Li, Chensheng Li, Ming-Qing Li, Yongxue Li, Bao-Shan Li, Jiao Li, Zhimei Li, Jun-Cheng Li, Yimeng Li, Jingming Li, Jinxia Li, Chunting Li, De-Tao Li, Shu Li, Julia Li, Chien-Feng Li, Huilan Li, Mei-Zhen Li, Xin-Ya Li, Zhengjie Li, Chunsheng Li, Liwei Li, Yan-Yan Li, Huijun Li, Chengyun Li, Chengjian Li, Ying-na Li, Guihua Li, Zhiyuan Li, Lijun Li, Supeng Li, Hening Li, Yiju Li, Yuanhe Li, Guangxiao Li, Fengxia Li, Peixin Li, Xueqin Li, Feng-Feng Li, Zu-Ling Li, Jialing Li, Xin Li, Yunjiu Li, Zonghong Li, Dayong Li, Ningyan Li, Lingjiang Li, Yuhan Li, Zhenghui Li, Fuyuan Li, Ailing Li, H-F Li, Chunxia Li, Chaochen Li, Zhen-Li Li, Tengyan Li, Xianlu Li, Jiaqi Li, Jiabei Li, Zhengying Li, Yali Li, Zhaoshui Li, Wenjing Li, Yu-Hui Li, Jingshu Li, Chuang Li, Jiajun Li, Can Li, Zhe Li, Han-Bo Li, Stephen Li, Shuangding Li, Mangmang Li, Zengyang Li, Kaiyuan Li, Chunyan Li, Runzhen Li, Xiaopeng Li, Xi-Hai Li, MengGe Li, Xuezhong Li, Anan Li, Luying Li, Jiajv Li, Pei-Lin Li, Xiaoquan Li, Wan-Xin Li, Ning Li, Ruobing Li, Yanxi Li, Xia Li, Yongjing Li, Meitao Li, Ziqiang Li, Huayao Li, Wen-Xi Li, Shenghao Li, Huixue Li, Jiqing Li, Boxuan Li, Hehua Li, Yucheng Li, Qingyuan Li, Yongqi Li, Fengqi Li, Zhigang Li, Yuqing Li, Guiyang Li, Guo-Qiang Li, Dujuan Li, Yanbo Li, Yuying Li, Shaofei Li, Sanqiang Li, Shaoguang Li, Hongyu Li, Min-Rui Li, Guangping Li, Shuqiang Li, Dan C Li, Huashun Li, Jinxin Li, Ganggang Li, Xinrong Li, Haoqi Li, Yayu Li, Handong Li, Huaixing Li, Yan-Nan Li, Xianglong Li, Minyue Li, Hong-Mei Li, Jing-Jing Li, Songhan Li, Mengxia Li, Conglin Li, Jutang Li, Qingli Li, Yongxiang Li, Miao Li, Songlin Li, Qilong Li, Dijie Li, Chenyu Li, Yizhe Li, Ke Li, Yan Bing Li, Jiani Li, Lianjian Li, Zhen-Hua Li, Yiliang Li, Chuan-Yun Li, Xinpeng Li, Hongxing Li, Wanyi Li, Gaoyuan Li, Mi Li, Youming Li, Qingrun Li, Dong-Yun Li, Guo Li, Jingxia Li, Xiu-Ling Li, Fuhai Li, Ruijia Li, Shuangfei Li, Yumiao Li, Fengfeng Li, Qinggang Li, Jiexi Li, Huixia Li, Kecheng Li, Junxu Li, Xingye Li, Xiangjun Li, Junya Li, Jiang Li, Huiying Li, Shengxian Li, Qingyang Li, Yuxi Li, Xiao-Dong Li, Chenxuan Li, Xinghuan Li, Zhaoping Li, Xingyu Li, Zhenlu Li, Xiaolei Li, Wenying Li, Huilong Li, Xiao-Gang Li, Honghui Li, Zhenhui Li, Cheung Li, Zhenming Li, Xuelian Li, Shu-Fen Li, Chunjun Li, Changyan Li, Mulin Jun Li, Yinghua Li, Shangjia Li, Yanjie Li, Jingjing Li, Suhong Li, Xinping Li, Chaoying Li, Siyu Li, Qiu Li, Juanjuan Li, Xiangyan Li, Guangzhen Li, Kunlun Li, Xiaoyu Li, Shiyun Li, Yaobo Li, Shiquan Li, Xuewang Li, Mei Li, Xiangdong Li, Jifang Li, Zhenjia Li, Wan Li, Manjiang Li, Zhizhong Li, Ding Yang Li, Xiaoya Li, Xiao-Li Li, Shan Li, Shitao Li, Lijia Li, Zehan Li, Chunqiong Li, Huiliang Li, Junjun Li, Chenlong Li, Shujin Li, Hui-Long Li, Zhao-Cong Li, Zhi-Wei Li, Wenxi Li, Weining Li, Wu-Jun Li, Chang-hai Li, Bin-Kui Li, Yumao Li, Yuqiu Li, Honglian Li, Xue-Yan Li, Ya-Zhou Li, Yuan-Yuan Li, Xiang-Jun Li, Hongyi Li, Y X Li, Chia Li, Yunyun Li, Zhen-Jia Li, Fu-Rong Li, Honghua Li, Lanjuan Li, Qiuxuan Li, Man-Zhi Li, Xiancheng Li, Yanmei Li, De-Jun Li, Junxian Li, Zhihua Li, Keqing Li, Shuwen Li, Minqi Li, Danxi Li, Saijuan Li, Lingjun Li, Mimi Li, Si-Xing Li, Deheng Li, Yingjie Li, Yaodong Li, Shigang Li, Yuan-Hai Li, Lujie Li, Gao-Fei Li, Minghao Li, Minle Li, Meifen Li, Yifeng Li, Le-Le Li, Huanqing Li, Ziwen Li, Yuhang Li, Yongqiu Li, Pu-Yu Li, Jianhua Li, Nan-Nan Li, Chanjuan Li, Hongming Li, Lan-Lan Li, Shuang Li, Yanchuan Li, Lingyi Li, Wanting Li, Bai-Qiang Li, Gong-Hua Li, Zhengyu Li, Chunmiao Li, Jiong-Ming Li, Yongqiang Li, Linsheng Li, Weiguang Li, Mingyao Li, Guoqing Li, Ze Li, Xiaomeng Li, R H L Li, Yuanze Li, Yunqi Li, Yuandong Li, Guisen Li, Jinglin Li, Dongyang Li, Mingfang Li, Honglong Li, Hanmei Li, Chenmeng Li, Changcheng Li, Shiyang Li, Shiyue Li, Jianing Li, Hanbo Li, Yinggao Li, Dingshan Li, Linlin Li, Xinsheng Li, Jin-Wei Li, Cheng-Tian Li, Jin-Jiang Li, Chang Li, Zhi-Xing Li, Yaxi Li, Ming-Han Li, Wei-Ming Li, Wenchao Li, Guangyan Li, Xuesong Li, Zhaosha Li, Jiwei Li, Yongzhen Li, Chun-Quan Li, Weifeng Li, Tao Li, Sichen Li, Wenhui Li, Xiankai Li, Qingsheng Li, Liangji Li, Yaxuan Li, Yuchan Li, Lixiang Li, Tian-wang Li, Jiaxi Li, Yalin Li, Jin-Liang Li, Pei-Zhi Li, Xiaoqiong Li, You Ran Li, Guanyu Li, Yixiao Li, Jinlan Li, Huizi Li, Jianping Li, Kathy H Li, Yun-Lin Li, Yadong Li, Yuhua Li, Sujing Li, Wenzhuo Li, Xuri Li, Y Li, Deqiang Li, Mingyue Li, Caixia Li, Zipeng Li, Hongli Li, Yun Li, Mengqiu Li, Ling-Ling Li, Yanfeng Li, Yaqin Li, Yu-He Li, Shasha Li, Xi Li, S-C Li, Siyi Li, Minmin Li, Manna Li, Chengwen Li, Dawei Li, Shu-Feng Li, Haojing Li, Xun Li, Ming-Jiang Li, Zhiyu Li, Ziyang Li, Sitao Li, Qian Li, Yaochen Li, Tinghua Li, Wenyang Li, Bohao Li, Zhenfen Li, Shuo Li, Wenming Li, Mingxuan Li, Si-Ying Li, Xinyi Li, Jenny J Li, Xue-zhi Li, Shuai Li, Anqi Li, Bingsong Li, Xiaoju Li, Xiaonan Li, Ting Li, Zhenyu Li, Xiang-Yu Li, Duan Li, Lei Li, Hongde Li, Fengqing Li, Na Li, Xunjia Li, Yanchang Li, Huibo Li, Ruixia Li, Nanzhen Li, Chuanfang Li, Bingjie Li, Hongxue Li, Pengsong Li, Ruotian Li, Xiaojing Li, Xinlin Li, Zong-Xue Li, En-Min Li, Chunya Li, Yan Ning Li, Honglin Li, Yu-Ying Li, Jinhua Li, Min-jun Li, Yuanheng Li, Qian-Qian Li, Chunxiao Li, Wenli Li, Shijun Li, Kuan Li, Mengze Li, Baoguang Li, Jie-Shou Li, Kaiwei Li, Zimeng Li, Mengmeng Li, W-B Li, Huangyuan Li, Lili Li, Binkui Li, Junxin Li, Yu-Sheng Li, Wei-Jun Li, Guoyan Li, Junjie Li, Fei-Lin Li, Nuomin Li, Shanglai Li, Shulin Li, Yanyan Li, Yue Li, Taibo Li, Junqin Li, Zhongcai Li, Xueying Li, Jun-Ru Li, JunBo Li, Zhaobing Li, Xiaoqi Li, Xiucui Li, Haihua Li, Linxin Li, Yu-Lin Li, Jen-Ming Li, Shujing Li, Tsai-Kun Li, Chen-Chen Li, Hongquan Li, Chuan F Li, Mengyun Li, Mingna Li, Yanxiang Li, Lanlan Li, Moyi Li, Xiyun Li, Yi-Wen Li, Ya-Pei Li, Huifeng Li, Rulin Li, Shihong Li, Lijuan Li, Shengbin Li, Yuanhong Li, Zhongjie Li, Zhenbei Li, Jingyu Li, Xuewei Li, Long Li, Shuangshuang Li, Wenjia Li, Min-Dian Li, Xiatian Li, Hongwei Li, Ding-Jian Li, Xiao-Qiang Li, Danni Li, Yangxue Li, Chengnan Li, Chuanyin Li, Min Li, Zhenzhou Li, Yiqiang Li, Pengyang Li, Kun-Xin Li, Xiawei Li, Binglan Li, Zesong Li, Xiangpan Li, Yutong Li, Mingfei Li, Shuwei Li, Yingnan Li, Ge Li, Mingdan Li, Xihe Li, Xinzhong Li, Jianfeng Li, Chenyao Li, Jun-Yan Li, Dexiong Li, Rongsong Li, Boru Li, Yinxiong Li, Ruixue Li, Zemin Li, Jixi Li, Chris Li, Jicheng Li, Hong-Yu Li, Chuanning Li, Weijian Li, Jiafei Li, Changhui Li, Yingying Li, Gaizhi Li, Chien-Hsiu Li, Xiangcheng Li, Siqi Li, Dechao Li, Chunxing Li, Wenxia Li, Guoxiang Li, Ziru Li, Qiao-Xin Li, Shu-Fang Li, Huang Li, Qiusheng Li, Man Li, Juxue Li, Weiqin Li, Xinming Li, Huayin Li, Xiao-yu Li, Jianyi Li, Yongjun Li, Mengyang Li, Guo-Jian Li, Guowei Li, Chenglong Li, Xingya Li, Nan Li, Gongda Li, Yajun Li, Wei-Ping Li, Yipeng Li, Mingxing Li, Nanjun Li, Xin-Yu Li, Chunyu Li, P H Li, Jinwei Li, Xuhua Li, Yu-Xiang Li, Ranran Li, Suping Li, Long Shan Li, Yanze Li, Jason Li, Xiao-Feng Li, Monica M Li, Fengjuan Li, W Li, Xianlun Li, Qi Li, Hainan Li, Yutian Li, Xiaoli Li, Xiliang Li, Shuangmei Li, Ying-Bo Li, Fei Li, Xionghui Li, Duanbin Li, Maogui Li, Dan Li, Sumei Li, Peilong Li, Hongmei Li, Kang Li, Yinghao Li, Xu-Wei Li, Mengsen Li, Lirong Li, Wenhong Li, Quanpeng Li, Audrey Li, Yijian Li, Yajiao Li, Guang Y Li, Xianyong Li, Qilan Li, Shilan Li, Qiuhong Li, Zongyun Li, Xiao-Yun Li, Guang-Li Li, Cheng-Lin Li, Bang-Yan Li, Enxiao Li, Jianrui Li, Yousheng Li, Wen-Ting Li, Guohua Li, Kezhen Li, Xingxing Li, Guoping Li, Ellen Li, A Li, Simin Li, Xue-Nan Li, Weiguo Li, Yijie Li, Xiaoying Li, Suwei Li, Shengsheng Li, Shuyu D Li, Jiandong Li, Ruiwen Li, Fangyong Li, Hong Li, Binru Li, Yuqi Li, Zihua Li, Yuchao Li, Hanlu Li, Xue-Peng Li, Jianang Li, Qing Li, Jiaping Li, Sheng-Tien Li, Yazhou Li, Shihao Li, Jun-Ling Li, Caesar Z Li, Weiyang Li, Feng Li, Lang Li, Peihong Li, Jin-Mei Li, Lisha Li, Feifei Li, Kejuan Li, Qinghong Li, Qiqiong Li, Cuicui Li, Kaibo Li, Xinxiu Li, Chongyi Li, Yi-Ying Li, Hanbing Li, Shaodan Li, Meng-Hua Li, Yongzheng Li, J T Li, Da-Hong Li, Xiao-mei Li, Jiejie Li, Ruihuan Li, Xiangwei Li, Baiqiang Li, Ziliang Li, Yaoyao Li, Mo Li, Yueguo Li, Zheng Li, Ming-Hao Li, Donghe Li, Congfa Li, Wenrui Li, Hongsen Li, Yong Li, Xiuling Li, Menghua Li, Jingqi Li, Ka Li, Kaixin Li, Fuping Li, Zhiyong Li, Jianbo Li, Xing-Wang Li, Chong Li, Xiao-Kang Li, Hanqi Li, Fugen Li, Yuwei Li, Yangyang Li, Dongfang Li, Xiaochen Li, Zizhuo Li, Zhuorong Li, X-H Li, Xianrui Li, Lan-Juan Li, Dong Sheng Li, Zhigao Li, Chenlin Li, Zihui Li, Xiaoxiao Li, Guoli Li, Le-Ying Li, Pengcui Li, Xiaoman Li, Huanqiu Li, Bing-Heng Li, Zhan Li, Weisong Li, Xinglong Li, Xiaohong Li, Xiaozhen Li, Yuan Hao Li, Jianchun Li, Wenxiang Li, Zhaoliang Li, Guo-Ping Li, Zhiyang Li, Cunxi Li, Zhifei Li, Jinhui Li, Ying Li, Yanshu Li, Jianlin Li, Yuanyou Li, Chongyang Li, Yumin Li, Wanyan Li, Longyu Li, Jinku Li, Guiying Li, X B Li, Zhisheng Li, Cuiling Li, Changgui Li, Xuekun Li, Yuguang Li, Wenke Li, Jianguo Li, Jiayi Li, En Li, Ximei Li, Shaoyong Li, Peihua Li, Kai-Wen Li, Suwen Li, Chang-Ping Li, Guangda Li, Guandu Li, Yixue Li, Junfeng Li, Xin-Chang Li, Jieming Li, Yue-Ying Li, Kongdong Li, Chunhui Li, Peiyu Li, Tongyao Li, Lian Li, Linfeng Li, Yuzhe Li, Xinmiao Li, Chenyang Li, Jiacheng Li, Chang-Yan Li, Qifang Li, Xiaohua Li, Vivian Li, Duanxiang Li, Xiaolin Li, Meiting Li, Justin Li, Xue-Er Li, Zhuangzhuang Li, Hongchang Li, Xiaohui Li, Cang Li, Xuepeng Li, Mingjiang Li, Youwei Li, Ronggui Li, Xingwang Li, Tiange Li, Yongjia Li, Dacheng Li, Xinmin Li, Zongyu Li, Luquan Li, Shujie Li, Jianyong Li, Guoxing Li, Zongchao Li, Yanbin Li, Jia Li, Shiliang Li, Haimin Li, Qinrui Li, Sheng-Qing Li, Yiming Li, Lingjie Li, Xiao-Tong Li, Tie Li, Yiwen Li, Baoqi Li, Wei-Bo Li, Leyao Li, Xiaoyi Li, Liyan Li, Xiao-Qin Li, Xiaokun Li, Xinke Li, Ming-Wei Li, Wenfeng Li, Minzhe Li, Jiajing Li, Karen Li, Yanlin Li, X Li, Liao-Yuan Li, Meifang Li, Yanjing Li, Yongkai Li, Maosheng Li, Ju-Rong Li, Jin Li, Shibo Li, Hangwen Li, Li-Na Li, Hengguo Li, An-Qi Li, Xuehua Li, Hui Li, AnHai Li, Chenli Li, Zhengrui Li, Rumei Li, Fangqi Li, Xiaoguang Li, Xian Li, Danjie Li, Yan-Yu Li, Vivian S W Li, Qinghua Li, Qinqin Li, Lipeng Li, Leilei Li, Ranchang Li, Defu Li, Lianyong Li, Amy Li, Zhou Li, Q Li, Haoyu Li, Xiaoyao Li, M-J Li, Jiao-Jiao Li, Rongling Li, Zhu Li, Tong-Ruei Li, Bizhi Li, Cheng-Wei Li, Wenwen Li, Jian'an Li, Guangqiang Li, Ben Li, Sichong Li, Wenyi Li, Yingxia Li, Meiyan Li, Qing-Min Li, Yonghe Li, Yun-Da Li, Xinwei Li, Shunhua Li, Yu-I Li, Mingxi Li, Jian-Qiang Li, Yingrui Li, Chenfeng Li, Qionghua Li, Guo-Li Li, Xingchen Li, Shen Li, Ziqi Li, Tianjiao Li, Gui-Rong Li, Yunfeng Li, Shufen Li, Yunpeng Li, Yueqi Li, Qiong Li, Xiao-Guang Li, Jiali Li, Zhencheng Li, Qiufeng Li, Songyu Li, Xu Li, Pinghua Li, Shi-Fang Li, Shude Li, Yaxiong Li, Zhibin Li, Zhenli Li, Qing-Fang Li, Yunxiao Li, Rosa J W Li, Hsin-Yun Li, Shengwen Li, Gui-Bo Li, XiaoQiu Li, Xueer Li, Zhi Li, Zhankui Li, Zihai Li, Yue-Jia Li, Haihong Li, Peifen Li, Taixu Li, Mingzhou Li, Jiejing Li, Meng-Miao Li, Meiying Li, Chunlian Li, Meng Li, Zhijie Li, Cun Li, Huimin Li, T Li, Ruifang Li, Xiao-xu Li, Man-Xiang Li, Cong Li, Yinghui Li, Chengbin Li, Feilong Li, Yuping Li, Sin-Lun Li, Mengfan Li, Weiling Li, Jie Li, Shiyan Li, Lianbing Li, G Li, Yanchun Li, Xuze Li, Zhi-Yong Li, Yukun Li, Wenjian Li, Jialin Li, He Li, Bichun Li, Hanqin Li, Xiong Bing Li, Qingjie Li, Wen Lan Li, Guoge Li, Han Li, Wen-Wen Li, Keying Li, Yutang Li, Minze Li, Xingcheng Li, Wanshun Li, Congxin Li, Hankun Li, Hongling Li, Xiangrui Li, Chaojie Li, Michelle Li, Caolong Li, Zhifan Li, J Li, Zhi-Jian Li, Jianwei Li, Yan-Guang Li, Jiexin Li, Hongyan Li, Ji-Min Li, Zhen-Xi Li, Peipei Li, Guangdi Li, Tian-Yi Li, Xiaxia Li, Yuefeng Li, Nien Li, Zhihao Li, Peiyuan Li, Yao Li, Zheyun Li, Tiansen Li, Chi-Yuan Li, Xiangfei Li, Xue Li, Zhonglin Li, Fen Li, Lin Li, Jieshou Li, Jinfang Li, Chenjie Li, Roger Li, Yanming Li, Hong-Lan Li, Mengqing Li, Ben-Shang Li, S L Li, Xionghao Li, Ming-Kai Li, Shunqing Li, Lan Li, Menglu Li, Huiqing Li, Yanwei Li, Yantao Li, Chien-Te Li, Wenyan Li, Xiaoheng Li, Zeyuan Li, Ruolin Li, Yongle Li, Hongqin Li, Zhenhao Li, Jonathan Z Li, Haying Li, Shao-Dan Li, Yong-Liang Li, Muzi Li, Gen Li, M Li, Dong-Ling Li, Chenwen Li, Jiehan Li, Yong-Jian Li, Le Li, Hongguo Li, Chenxin Li, Yongsen Li, Qingyun Li, Pengyu Li, Si-Wei Li, Ai-Qin Li, Zichao Li, Manru Li, Caili Li, Yingxi Li, Yuqian Li, Guannan Li, Wei-Dong Li, Cien Li, Qingyu Li, Xijing Li, Jingshang Li, Xingyuan Li, Dehua Li, Ya-Feng Li, Wenlong Li, Yanjiao Li, Jia-Huan Li, Yuna Li, Xudong Li, Guoxi Li, Xingfang Li, Shugang Li, Shengli Li, Jisheng Li, Rongyao Li, Xuan Li, Yongze Li, Ru Li, Yongxin Li, Lu Li, Jiangya Li, Yiche Li, Yilang Li, Zhuo-Rong Li, Qinglin Li, Bingbing Li, Runzhi Li, Yunshen Li, Jingchun Li, Qi-Jing Li, Hexin Li, H J Li, Yanping Li, Zhenyan Li, Ji Xia Li, Meizi Li, Yu-Ye Li, Qing-Wei Li, Qiang Li, Yuezheng Li, Hsiao-Hui Li, L I Li, Zhengnan Li, Jianglong Li, Hongzheng Li, Laiqing Li, Zhongxia Li, Ningyang Li, Guangquan Li, Xiaozheng Li, Hui-Jun Li, Shun Li, Xuefei Li, Guojun Li, Senlin Li, Hung Li, Jinping Li, Sainan Li, Huili Li, Jinghui Li, Zulong Li, Chengsi Li, Hongzhe K Li, P Li, Fulun Li, Xiao-Qiu Li, Jiejia Li, Yonghao Li, Mingli Li, Yehong Li, Yi-Yang Li, Zhihui Li, Fujun Li, Pei Li, Quanshun Li, Yongping Li, Liguo Li, Ni Li, Weimin Li, Mingxia Li, Xue-Hua Li, M V Li, Luxuan Li, Qiang-Ming Li, Yakui Li, Huafu Li, Xinye Li, Shichao Li, Gan Li, Chunliang Li, Ruiyang Li, Dapei Li, Zejian Li, Lihong Li, Chun Li, Jianan Li, Wenfang Li, Haixia Li, Sung-Chou Li, Xiangling Li, Lianhong Li, Jingmei Li, Ao Li, Yitong Li, Siwen Li, Yanlong Li, Cheng Li, Kui Li, Zhao Li, Tiegang Li, Yunxu Li, Shuang-Ling Li, Zhong Li, Xiao-Long Li, Xiaofei Li, Hung-Yuan Li, Xuanfei Li, Zilin Li, Zhang Li, Jianxin Li, Mingqiang Li, H Li, Xiaojiao Li, Dongliang Li, Yinzhen Li, Chenxiao Li, Hongjia Li, Xiao-Jing Li, Li-Min Li, Yunsheng Li, Xiangqi Li, Jian Li, Y H Li, Jia-Peng Li, Baichuan Li, Daoyuan Li, Haibo Li, Wenqi Li, Zhenzhe Li, Xiao-Jun Li, Jian-Mei Li, Kaimi Li, Yan-Hong Li, Peiran Li, Shi Li, Xueling Li, Qiao Li, Yi-Yun Li, Xiao-Cheng Li, Conghui Li, Xiaoxiong Li, Wanni Li, Yike Li, Yihan Li, Chitao Li, Haiyang Li, Jiayu Li, Xiaobai Li, Junsheng Li, Pingping Li, Wen-Ya Li, Mingquan Li, Yunlun Li, Suran Li, Rongxia Li, Yingqin Li, Yuanfang Li, Guoqin Li, Qiner Li, Huiqin Li, Shanhang Li, Jiafang Li, Chunlin Li, Han-Bing Li, Zongzhe Li, Jisen Li, Yikang Li, Si-Yuan Li, Caihong Li, Hongmin Li, Yajing Li, Peng Peng Li, Kenli Li, Guanglu Li, Benyi Li, Yuquan Li, Xiushi Li, Hongzhi Li, Jian-Jun Li, Dongmin Li, Fengyi Li, Yanling Li, Chengxin Li, Juanni Li, Xiaojiaoyang Li, C Li, Jian-Shuang Li, Xinxin Li, You-Mei Li, Chenglan Li, Dazhi Li, Yubin Li, Beixu Li, Yuhong Li, Guiyuan Li, Di Li, Fengqiao Li, Yanbing Li, Suk-Yee Li, Yuanyuan Li, Jufang Li, Shengjie Li, Xiaona Li, Shanyi Li, Hongbo Li, Chih-Chi Li, Xinhui Li, Zecai Li, Qipei Li, Xiaoning Li, Xiyue Li, Jun Li, Minghua Li, Zhuoran Li, Tianchang Li, Hongru Li, Shiqi Li, Mei-Ya Li, Wuyan Li, Mingzhe Li, Yi-Ling Li, Hongjuan Li, Yingjian Li, Zhirong Li, Wang Li, Mingyang Li, Weijun Li, Boyang Li, Senmao Li, Cai Li, Mingjie Li, Ling-Jie Li, Hong-Chun Li, Jingcheng Li, Ivan Li, Yaying Li, Mengshi Li, Liqun Li, Manxia Li, Ya Li, Changxian Li, Wen-Chao Li, Dan-Ni Li, Sunan Li, Zhencong Li, Chunqing Li, Jiong Li, Lai K Li, Yanni Li, Daiyue Li, Bingong Li, Huifang Li, Xiujuan Li, Yongsheng Li, Lingling Li, Chunxue Li, Yunlong Li, Xinhua Li, Jianshuang Li, Juanling Li, Minerva X Li, Xinbin Li, Alexander H Li, Xue-jing Li, Yuling Li, Ding Li, Wendeng Li, Xianlin Li, Yetian Li, Chuangpeng Li, Mingrui Li, Ming-Yang Li, Linyan Li, Yanjun Li, Shengze Li, Jiequn Li, Zhongding Li, Hewei Li, Da-Jin Li, Jiangui Li, Zhengyang Li, Cyril Li, Xinghui Li, Yuefei Li, Xiao-kun Li, Xinyan Li, Yuanhao Li, Xiaoyun Li, Ji-Lin Li, Congcong Li, Yushan Li, Ping'an Li, Juan Li, Huan Li, Weiping Li, Changjiang Li, Chengping Li, He-Zhen Li, G-P Li, Xiaobin Li, Shaoqi Li, Yuehua Li, Yinliang Li, Jinfeng Li, Wen Li, Shiheng Li, Jiangan Li, Yu-Kun Li, Weihai Li, Hsiao-Fen Li, Zhaojin Li, Bingxin Li, Mengjiao Li, Wenjuan Li, Meng-Meng Li, Wenyu Li, Chia-Yang Li, Tianxiang Li, Liangkui Li, Tian-chang Li, Hairong Li, Yahui Li, Su Li, Xi-Xi Li, Wenlei Li, Mei-Lan Li, Wenjun Li, Jiaxin Li, Haiyan Li, Ming D Li, Chenguang Li, Xujun Li, Ruyue Li, Chi-Ming Li, Xiaolian Li, Dandan Li, Yi-Ning Li, Yunan Li, Zechuan Li, Zhijun Li, Jiazhou Li, Sherly X Li, Wanling Li, Ya-Ge Li, Yinyan Li, Qijun Li, Rujia Li, Guangli Li, Zhiwei Li, Lixia Li, Xueshan Li, Yunrui Li, Yuhuang Li, Shanshan Li, Jiangbo Li, Xiaohan Li, Wan-Shan Li, Zhongwen Li, Huijie Li, W W Li, Yalan Li, Yiyang Li, Jing-gao Li, Fengxiang Li, Xuejun Li, Nana Li, Shunwang Li, Chao Li, Yaqing Li, Bingsheng Li, Yaqiao Li, Jingui Li, Huamao Li, Xiankun Li, Jingke Li, Xiaowei Li, Tianyao Li, Junming Li, Jianfang Li, Shubo Li, Qi-Fu Li, Zi-Zhan Li, Haoran Li, Hai-Yun Li, Zhongxian Li, Xiaoliang Li, Xinyuan Li, Maoquan Li, H-J Li, Zhixiong Li, Chumei Li, Shijie Li, Lingyan Li, Zhanquan Li, Wenguo Li, Fangyuan Li, Xuhang Li, Xiaochun Li, Chen-Lu Li, Xinjian Li, Jialun Li, Rui Li, Zilu Li, Xuemin Li, Zezhi Li, Sheng-Fu Li, Xue-Fei Li, Yudong Li, Shanpeng Li, Hongjiang Li, Wei-Na Li, Dong-Run Li, Yunxi Li, Jingyun Li, Binghua Li, Xuyi Li, Hanjun Li, Yunchu Li, Zhengyao Li, Jin-Qiu Li, Qihua Li, Jiaxuan Li, Jinghao Li, Y-Y Li, Xiaofang Li, Tuoping Li, Pengyun Li, Guangjin Li, Xutong Li, Lin-Feng Li, Ranwei Li, Ziqing Li, Kai Li, Keanning Li, Wei-Li Li, Yongjin Li, Shuangxiu Li, Chenhao Li, Ling Li, Weizu Li, Deming Li, Peiqin Li, Xiaodong Li, Nanxing Li, Qihang Li, Jianrong Li, Baoguo Li, Zhehui Li, Chenghao Li, Jiuyi Li, Luyao Li, Chun-Xu Li, Desheng Li, Weike Li, Long-Yan Li, Zhixuan Li, Chuanbao Li, Fuyu Li, Chuzhong Li, M D Li, Lingzhi Li, Yuan-Tao Li, Kening Li, Guilan Li, Wanshi Li, Hengtong Li, Ling-Zhi Li, Yifan Li, Ya-Li Li, Xiao-Sa Li, Songyun Li, Xiaoran Li, Bolun Li, Kunlin Li, Linchuan Li, Jiachen Li, Shu-Qi Li, Haibin Li, Zehua Li, Huangbao Li, Guo-Chun Li, Xinli Li, Mengyuan Li, S Li, Wenqing Li, Wenhua Li, Caiyun Li, Congye Li, Xinrui Li, Wensheng Li, Dehai Li, Jiannan Li, Qingshang Li, Guanbin Li, Hanbin Li, Zhiyi Li, Xing Li, Wanwan Li, Jia Li Li, Zhaoyong Li, SuYun Li, Shiyi Li, Wan-Hong Li, Mingke Li, Suchun Li, Xiaoyuan Li, Huanhuan Li, Yanan Li, Zongfang Li, Yang Li, Jiayan Li, YueQiang Li, Xiangping Li, H-H Li, Jinman Li, BoWen Li, Duoyun Li, Dongdong Li, Yimei Li, Hao Li, Liliang Li, Mengxi Li, Keyuan Li, Zhi-qiang Li, Shaojing Li, S S Li, Yi-Ting Li, Jiangxia Li, Yujie Li, Tong Li, Yilong Li, Lihua Li, Xue-Lian Li, Yan-Li Li, Zhiping Li, Haiming Li, Yansen Li, Gaijie Li, Zhi-Yuan Li, Hai Li, Yuemei Li, Yanli Li, Jingfeng Li, Kaibin Li, Yuan-Jing Li, Xuefeng Li, Wenjie Li, Xiaohu Li, Ruikai Li, Xiao-Hong Li, Mengjuan Li, Yinglin Li, Yaofu Li, Ren-Ke Li, Qiyong Li, Ruixi Li, Yi Li, Baosheng Li, Zhonglian Li, Mian Li, Yujun Li, Dalin Li, Lixi Li, Jin-Xiu Li, Kun Li, Qizhai Li, Jiwen Li, Pengju Li, Peifeng Li, Zhouhua Li, Ai-Jun Li, Qingqin S Li, Honglei Li, Yueting Li, Guojin Li, Xin-Yue Li, Dingchen Li, YaJie Li, Xiaoling Li, Jixuan Li, Yanqing Li, Zijian Li, Zhandong Li, Xuejie Li, Peining Li, Congjiao Li, Meng-Jun Li, Gaizhen Li, Huilin Li, Liang Li, Songtao Li, Fusheng Li, Huafang Li, Dai Li, Meiyue Li, Chenlu Li, Keshen Li, Kechun Li, Nianyu Li, Yuxin Li, Shaoliang Li, X-L Li, Shawn S C Li, Shu-Xin Li, Hong-Zheng Li, Cuiguang Li, Dongye Li, Qun Li, Tianye Li, Zhen Li, Yuan Li, Chunhong Li, F Li, Mengling Li, Kunpeng Li, Jia-Da Li, Zhenghao Li, Chun-Bo Li, Zhantao Li, Baoqing Li, Pu Li, Xinle Li, Xingli Li, Bingkun Li, Nien-Chi Li, Wuguo Li, Tiewei Li, Bing-Hui Li, Daniel Tian Li, Rong-Bing Li, Jingyong Li, Honggang Li, Rong Li, Wei-Yang Li, Shikang Li, Mingkun Li, Binxing Li, Shi-Ying Li, Zixiao Li, Ming Xing Li, Guixin Li, Quanzhang Li, Ming-Xing Li, Marilyn Li, Da-wei Li, Bei-Bei Li, Shishi Li, Hong-Lian Li, Haitong Li, Xiumei Li, Melody M H Li, Yuli Li, Ruibing Li, Qingfang Li, Peibo Li, Qibing Li, Huanjun Li, Heng Li, Wende Li, Chung-Hao Li, Liuzheng Li, Zhanjun Li, Yifei Li, Tianming Li, Chang-Sheng Li, Xiao-Na Li, Tianyou Li, Jipeng Li, Xidan Li, Yixing Li, Chengcheng Li, Yu-Jin Li, Longxuan Li, Baoting Li, Huiyou Li, Ka Wan Li, Shi-Guang Li, Wenxiu Li, Binbin Li, Xinyao Li, Zhuang Li, Yu-Hao Li, Gui-xing Li, Shunle Li, Shilin Li, Niu Li, Siyue Li, Diyan Li, Mengyao Li, Shili Li, Yixuan Li, Shan-Shan Li, Meiqing Li, Zhuanjian Li, Gerard Li, Yuyun Li, Hengyu Li, Zhiqiong Li, Yinhao Li, Zonglin Li, Pik Yi Li, Junying Li, Jingxin Li, Mufan Li, Chun-Lai Li, Defeng Li, Shiya Li, Zu-guo Li, Xin-Zhu Li, Xiao-Jiao Li, Jia-Xin Li, Kuiliang Li, Pindong Li, Hualian Li, Youchen Li, Junhong Li, Li Li, W Y Li, Hanxue Li, Lulu Li, Yi-Heng Li, Xiaoqin Li, L P Li, Runbing Li, Chunmei Li, Mingjun Li, Yuanhua Li, Qiaolian Li, Yanmin Li, Ji-Cheng Li, Jingyi Li, Yuxiang Li, Haolong Li, Hao-Fei Li, Xuanzheng Li, Peng-li Li, Quan Li, Yining Li, Xue-Ying Li, Xiurong Li, Huijuan Li, Haiyu Li, Xu-Zhao Li, Yunze Li, Yanzhong Li, Kainan Li, Guohui Li, Yongzhe Li, Qingfeng Li, Tianyi Li, Xiaoyan Li, Nanlong Li, Ping Li, Xu-Bo Li, Nien-Chen Li, Fangzhou Li, Yue-Chun Li, Jiahui Li, Huiping Li, Kangyuan Li, Yuanchuang Li, Biao Li, Haiying Li, Yunting Li, Xiaoxuan Li, Anyao Li, Hongliang Li, Qing-Chang Li, Shengbiao Li, Hong-Yan Li, Yue-Rui Li, Ruidong Li, Dalei Li, Zongjun Li, Y M Li, Changqing Li, Hanting Li, Dong-Jie Li, Sijie Li, Dengxiong Li, Xiaomin Li, Meilan Li, D C Li, Andrew C Li, Jianye Li, Yi-Shuan J Li, Tinghao Li, Qiuyan Li, Zhouxiang Li, Tingguang Li, Yun-tian Li, Jianliang Li, Xiangyang Li, Guangzhao Li, Chunjie Li, Yixi Li, Shuyu Dan Li, S A Li, Tianfeng Li, Anna Fen-Yau Li, Minghui Li, Jiangfeng Li, Jinjie Li, Liming Li, Jie-Pin Li, Junyi Li, Kaiyi Li, Wenqun Li, Dongtao Li, Fengyuan Li, Guixia Li, Yinan Li, Aoxi Li, Zuo-Lin Li, Chenxi Li, Yuanjing Li, Zhengwei Li, Linqi Li, Xixi Li, Bingjue Li, Binghu Li, Yan-Chun Li, Suiyan Li, Yu-Hang Li, Qiaoqiao Li, Zhenguang Li, Xiaotian Li, Jia-Ru Li, Shuhui Li, Shu-Hong Li, Chun-Xiao Li, Pei-Qin Li, Shuyue Li, Mengying Li, Quan-Zhong Li, Fangyan Li, Tongzheng Li, Yihong Li, Dali Li, Duo Li, Yaxian Li, Zhiming Li, Xuemei Li, Xueting Li, Hongxia Li, Yongting Li, Danyang Li, Zhenjun Li, Ren Li, Tiandong Li, Lanfang Li, Hongye Li, Mingwei Li, Di-Jie Li, Bo Li, Jinliang Li, Wenxin Li, Qiji Li, W J Li, Zhipeng Li, Zhijia Li, Xiaoping Li, Jingtong Li, Linhong Li, Taoyingnan Li, Lucy Li, Lieyou Li, Zhengpeng Li, Xiayu Li, Huabin Li, Mao Li, Baolin Li, Cuilan Li, Yuting Li, Yongchao Li, Xiaobo Li, Xiaoting Li, Ruotai Li, Meijia Li, Shujiao Li, Yaojia Li, Weirong Li, Xiao-Yao Li, Kun-Ping Li, Weihua Li, Shangming Li, Yaqi Li, Yibo Li, Gui-Hua Li, Zhihong Li, Yandong Li, Runzhao Li, Chaowei Li, Xiang-Dong Li, Huiyuan Li, Yuchun Li, Yingjun Li, Xiufeng Li, Yanxin Li, Xiaohuan Li, Ying-Qin Li, Boya Li, Lamei Li, O Li, Fan Li, Suheng Li, Joyce Li, Jun Z Li, Yiheng Li, Taiwen Li, Hui-Ping Li, Xiaorong Li, Junru Li, Zhiqiang Li, Hecheng Li, Jiangchao Li, Haifeng Li, Changkai Li, Yueping Li, Liping Li, Rena Li, Jiangtao Li, Yu-Jui Li, Zhenglong Li, Yajuan Li, Rui-Jún Eveline Li, Xuanxuan Li, Bing-Mei Li, Chaoqian Li, Yunman Li, Shuhua Li, Yu-Cheng Li, Chunying Li, Yirun Li, Haomiao Li, Leipeng Li, Weiheng Li, Qianqian Li, Baizhou Li, YiQing Li, Zhengliang Li, Han-Ru Li, Weijie Li, Sheng Li, Wei-Qin Li, Guoyin Li, Yaqiang Li, Qingxian Li, Zongyi Li, Dan-Dan Li, Yeshan Li, Qiwei Li, Zirui Li, Yongpeng Li, Chengjun Li, Keke Li, Jianbin Li, Chanyuan Li, Shiying Li, Jianxiong Li, Huaying Li, Ji Li, Tuojian Li, Yixin Li, Ziyue Li, Zhongzhe Li, Juntong Li, Xiang Li, Yumei Li, Xiang-Ping Li, Chaonan Li, Wenqiang Li, Yu-Chia Li, Pei-Shan Li, Zaibo Li, Heying Li, Shaomin Li, Guangming Li, Xuan-Ling Li, Yuxuan Li, Bingshan Li, Xiaoqiang Li, Jiahao Li, Hanxiao Li, Jiansheng Li, Shuying Li, Shibao Li, Kunlong Li, Pengjie Li, Xiaomei Li, Ruijin Li
articles
Menghan Lv, Xuan Wang, Xiayue He +4 more · 2025 · Frontiers in psychiatry · Frontiers · added 2026-04-24
Obesity and dysregulated cytokine levels are prevalent in schizophrenia patients undergoing antipsychotic treatment. While cytokines are implicated in obesity, their relationship with psychopathology Show more
Obesity and dysregulated cytokine levels are prevalent in schizophrenia patients undergoing antipsychotic treatment. While cytokines are implicated in obesity, their relationship with psychopathology in schizophrenia remains underexplored. This study investigated associations between body mass index (BMI), cytokine levels, and clinical symptoms in chronic schizophrenia patients. In this cross-sectional study,201chronic schizophrenia patients (Chinese Han population) were stratified into high BMI (BMI≥25kg/m A significant negative correlation was observed between BMI and IL-2( Higher BMI in chronic schizophrenia is associated with reduced IL-2 levels, attenuated negative symptoms, and adverse lipid profiles. TNF-α may modulate psychopathology severity. These findings highlight complex interactions between metabolic dysregulation, immune markers, and clinical manifestations in schizophrenia. Show less
📄 PDF DOI: 10.3389/fpsyt.2025.1574041
APOB
Yunsheng Zhang, Dingbang Ding, Shaofei Li +8 more · 2025 · Poultry science · Elsevier · added 2026-04-24
DHAV-3 is one of the main causative agents of duck viral hepatitis (DVH), an acute and highly lethal infectious disease in duck industry. However, the understanding of the pathogenesis of this virus i Show more
DHAV-3 is one of the main causative agents of duck viral hepatitis (DVH), an acute and highly lethal infectious disease in duck industry. However, the understanding of the pathogenesis of this virus in ducklings is limited. To dissect the molecular characteristics associated with pathobiology of ducklings to DHAV-3, we applied single-cell RNA-sequencing approach to profile the transcriptome of 1.4 million cells from 14 livers of DHAV-3 susceptible (S) and resistant (R) ducklings during viral infection and 4 uninfected healthy controls. We found that infected S ducks exhibited the activation of type I and II interferon pathways with elevated expression of interferon-stimulated genes (ISGs) compared to infected R ducks and healthy controls. DHAV-3 promoted proinflammatory phenotype and inhibited the cell apoptosis pathway of Kupffer cells of S ducks. Furthermore, we observed the elevated expression of host factor PLAC8 in S ducks and validated its ability to facilitate the infection of DHAV-3. We identified significant dysregulation of various genes in complement and coagulation cascades in hepatocytes2 exclusive to S ducks, together with over-secretion of ANGPTL4 from endothelial cells in S ducks which is confirmed to promote cellular migration, suggesting etiology of coagulopathic complications in ducks with severe DVH. Collectively, this study provides a rich resource for understanding the inflammatory immune signatures and cell communications underlying the pathogenesis of DHAV-3 infection, which may accelerate the development of better diagnostic methods and strategies for controlling this disease. Show less
📄 PDF DOI: 10.1016/j.psj.2025.104798
ANGPTL4
Hui Wang, Timothy S Chang, Beth A Dombroski +64 more · 2025 · Movement disorders : official journal of the Movement Disorder Society · Wiley · added 2026-04-24
The 17q21.31 region with various structural forms characterized by the H1/H2 haplotypes and three large copy number variations (CNVs) represents the strongest risk locus in progressive supranuclear pa Show more
The 17q21.31 region with various structural forms characterized by the H1/H2 haplotypes and three large copy number variations (CNVs) represents the strongest risk locus in progressive supranuclear palsy (PSP). To investigate the association between CNVs and structural forms on 17q.21.31 with the risk of PSP. Utilizing whole genome sequencing data from 1684 PSP cases and 2392 controls, the three large CNVs (α, β, and γ) and structural forms within 17q21.31 were identified and analyzed for their association with PSP. We found that the copy number of γ was associated with increased PSP risk (odds ratio [OR] = 1.10, P = 0.0018). From H1β1γ1 (OR = 1.21) and H1β2γ1 (OR = 1.24) to H1β1γ4 (OR = 1.57), structural forms of H1 with additional copies of γ displayed a higher risk for PSP. The frequency of the risk sub-haplotype H1c rises from 1% in individuals with two γ copies to 88% in those with eight copies. Additionally, γ duplication up-regulates expression of ARL17B, LRRC37A/LRRC37A2, and NSFP1, while down-regulating KANSL1. Single-nucleus RNA-seq of the dorsolateral prefrontal cortex analysis reveals γ duplication primarily up-regulates LRRC37A/LRRC37A2 in neuronal cells. The copy number of γ is associated with the risk of PSP after adjusting for H1/H2, indicating that the complex structure at 17q21.31 is an important consideration when evaluating the genetic risk of PSP. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. Show less
📄 PDF DOI: 10.1002/mds.30150
KANSL1
Chaoping Chen, Chenhao Li, Qingru Zhu +4 more · 2025 · European journal of medical research · BioMed Central · added 2026-04-24
Lifestyle improvement may help reverse prediabetes. Indicators such as Life's Essential 8 (LE8) and biological aging measures (phenotypic age, cardiovascular biological age) partially reflect metaboli Show more
Lifestyle improvement may help reverse prediabetes. Indicators such as Life's Essential 8 (LE8) and biological aging measures (phenotypic age, cardiovascular biological age) partially reflect metabolic status in prediabetes, but their predictive value for cardiovascular mortality and stroke in this population remains unclear. We analyzed data from 74,678 White participants with prediabetes in the UK Biobank, defined by either HbA1c (5.7-6.4%) or fasting glucose (6.1-6.9 mmol/L). Follow-up continued until October 10, 2023. Cox regression was used to examine associations between LE8, phenotypic age (PhenoAge), cardiovascular biological age (CBA), and outcomes of cardiovascular (CVD) mortality and stroke. Restricted cubic spline (RCS) models identified biological age risk thresholds. Mediation analysis assessed whether proteins such as CST3, EFEMP1, FES, IGFBP2, IGFBP6, LPA, PCSK9, and TIMP1 mediated these effects. Over a median follow-up of 13.4 years, 2263 participants died from CVD causes. Each 1-year increase in CBA or PhenoAge was associated with a ~ 10% higher risk of CVD mortality (CBA aHR = 1.10; PhenoAge aHR = 1.09; both P < 0.001), while each 1-point increase in LE8 score was linked to a 3% lower risk (HR = 0.97, P < 0.001). The risk biological ages for these two indicators were also identified: PhenoAge ≥ 58.52 years and CBA ≥ 62.42 years. Similar trends were observed for stroke. Mediation analysis revealed that CST3, TIMP1, IGFBP2, and IGFBP6 contributed to the biological pathways between aging/lifestyle and CVD outcomes. The combined LE8 and PhenoAge model showed the strongest predictive performance for CVD mortality (AUC = 0.716) and stroke (AUC = 0.638) over 15 years. LE8 combined with phenotypic age provides prognostic value for CVD outcomes in prediabetes. These findings highlight the potential of lifestyle modification and delayed biological aging in reversing prediabetes and underscore comorbidity-related proteins as promising therapeutic targets. Show less
📄 PDF DOI: 10.1186/s40001-025-03218-7
LPA
Tao Jiang, Chenhao Li, Yufen Li +8 more · 2025 · Journal of ethnopharmacology · Elsevier · added 2026-04-24
The Roucongrong Pill (RCRP), originating from the historical General Medical Collection of Royal Benevolence, is frequently used to treat postmenopausal osteoporosis (PMOP). Despite its prevalent appl Show more
The Roucongrong Pill (RCRP), originating from the historical General Medical Collection of Royal Benevolence, is frequently used to treat postmenopausal osteoporosis (PMOP). Despite its prevalent application, the specific anti-osteoporotic mechanisms of RCRP remain to be elucidated. This study aims to elucidate the therapeutic mechanism of RCRP in the context of ovariectomy (OVX)-induced PMOP in rats. By employing an integrative approach, the research combines medicinal chemistry, gut microbiota (GM) profiling, metabolomics, MetOrigin traceability, network pharmacology, molecular docking, and molecular dynamics simulations to deliver a comprehensive analysis. Sprague-Dawley (SD) rats underwent bilateral OVX to establish a PMOP model. The therapeutic efficacy of RCRP was evaluated through bone metrics (BMD, bone strength, BV/TV, Tb.Sp), hematoxylin and eosin (H&E) histological assessment, and bone metabolism markers (OPG, BALP, TRACP-5b, β-CTX, RANKL). Fecal metabolomics and 16S rDNA sequencing were employed to assess the influence of RCRP on GM and metabolite profiles. Furthermore, MetOrigin facilitated the traceability analysis of relevant metabolites. Molecular docking identified potential RCRP compounds with anti-PMOP activity, while their stability and protein interactions were assessed through molecular dynamics simulations. Network pharmacology further confirms the targets of action. RCRP alleviated PMOP in rats, enhancing bone strength, cortical and trabecular BMD, BV/TV, and serum OPG levels, while reducing Tb.Sp, serum BALP, TRACP-5b, β-CTX, and RANKL concentrations. A total of twenty-six distinct metabolites were identified, of which ten-tribufos, sulfoacetic acid, betamethasone dipropionate, 9-oxooctadeca-10,12,15-trienoic acid, menatetrenone, piperlongumine, maltopentaose, enol-phenylpyruvate, catechol, pentaacetate, and (+)-2-methylpropanoic acid-exhibited correlations with six GM species: Turicibacter, Roseburia, Colidextribacter, Helicobacter, Odoribacter, and Lachnoclostridium, as determined by Spearman's correlation analysis. Notably, MetOrigin revealed the microbial metabolism of taurine and hypotaurine, along with host-specific steroid hormone synthesis. Computational docking studies demonstrated robust interactions between five RCRP-derived steroids (hydroxyecdysone, corticosterone, trilostane, 5α-androstan-3,6,17-trione, and cortisol) and key enzymes (estradiol 17α-dehydrogenase and UDP-glucuronosyltransferase), suggesting a potential enhancement of therapeutic efficacy against PMOP. Furthermore, molecular dynamics simulations indicated stable interactions between hydroxyecdysone and two proteins, with binding free energies of -67.427 kJ/mol and -156.948 kJ/mol, respectively. Through network pharmacology and molecular docking approaches, potential targets of these metabolites were identified, including estrogen receptors ESR1 and ESR2, dual specificity phosphatase 6 (DUSP6), sex hormone-binding globulin (SHBG), prostaglandin E receptor 4 (PTGER4), cannabinoid receptor 2 (CNR2), cathepsin K (CTSK), and androgen receptor (AR). RCRP effectively mitigates OVX-induced bone loss in PMOP rats by modulating GM and associated metabolites, along with their potential targets and key metabolic pathways, including taurine and hypotaurine metabolism, as well as steroid hormone biosynthesis. These findings offer new insights into the therapeutic mechanisms by which RCRP may alleviate PMOP. Show less
no PDF DOI: 10.1016/j.jep.2024.118873
DUSP6
Jimmy H Mo, Chao Zhai, Kwangsek Jung +4 more · 2025 · iScience · Elsevier · added 2026-04-24
Vitellogenin is thought to share a common ancestor with human apolipoprotein B (ApoB) for systemic lipid transport. In
📄 PDF DOI: 10.1016/j.isci.2025.111860
APOB
Nolan Priedigkeit, Beth Harrison, Robert Shue +27 more · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research · added 2026-04-24
Inflammatory breast cancer (IBC) is a rare and clinically distinct form of breast cancer associated with poor outcomes. The biological mechanisms driving IBC remain poorly understood, partly due to li Show more
Inflammatory breast cancer (IBC) is a rare and clinically distinct form of breast cancer associated with poor outcomes. The biological mechanisms driving IBC remain poorly understood, partly due to limited large-scale genomic studies that directly compare IBC with non-IBC cases. We conducted a retrospective analysis of 140 patients with IBC (68 primary tumors and 72 metastatic tumors) and 2,317 patients with non-IBC (700 primary tumors, 65 local recurrences, and 1,552 metastases). We compared clinicopathologic features, single-nucleotide variants, copy-number variants, tumor mutational burden, and exploratory survival outcomes between IBC and non-IBC tumors. The most frequent somatic alterations in IBC were detected in TP53 (72%), ERBB2 (32%), PIK3CA (24%), CCND1 (12%), MYC (9%), FGFR1 (8%), and GATA3 (8%). Multivariate logistic regression revealed a significant enrichment of TP53 single-nucleotide variants in IBC, particularly in HER2+ and hormone receptor-positive disease. Tumor mutational burden did not differ between IBC and non-IBC cases. In HER2+ disease, a pathway analysis revealed an enrichment of NOTCH pathway alterations. TP53, CCND1, and RB1 alterations were associated with poor outcomes in IBC. This study provides a comprehensive resource of somatic alterations in a large cohort of patients with metastatic IBC and non-IBC, highlighting genomic features associated with worse outcomes. Our findings reveal a significant enrichment of TP53 mutations, reinforcing its critical role in IBC pathogenesis. Few other distinct differences in IBC were observed, suggesting further investigations-beyond bulk sequencing of the somatic genome-are required to better understand the biology driving this aggressive disease. Show less
📄 PDF DOI: 10.1158/1078-0432.CCR-24-2081
FGFR1
Jing Gan, Yuncong Wang, Zhuoran Shi +13 more · 2025 · NPJ precision oncology · Nature · added 2026-04-24
Increasing evidence underscores the driving role of coding and non-coding variants in cancer development. Analyzing gene sets in biological processes offers deeper insights into the molecular mechanis Show more
Increasing evidence underscores the driving role of coding and non-coding variants in cancer development. Analyzing gene sets in biological processes offers deeper insights into the molecular mechanisms of carcinogenesis. Here, we developed geMER to identify candidate driver genes genome-wide by detecting mutation enrichment regions within coding and non-coding elements. We subsequently designed a pipeline to identify a core driver gene set (CDGS) that broadly promotes carcinogenesis across multiple cancers. CDGS comprising 25 genes for 25 cancers displayed instability in DNA aberrations. Variants within the TTN enrichment region may influence the folding of the I-set domain by altering local polarity or side-chain chemistry properties of amino acids, potentially disrupting its antigen-binding capacity in LUAD. Multi-omics analysis revealed that APOB emerged as a candidate oncogene in LIHC, whose genetic alterations within the enrichment region may activate key TFs, upregulate DNA methylation levels, modulate critical histone modifications, and enhance transcriptional activity in the HepG2 and A549 cell lines compared to Panc1. Additionally, CDGS mutation status was an independent prognostic factor for the pan-cancer cohort. High-risk patients tended to develop an immunosuppressive microenvironment and demonstrated a higher likelihood of responding to ICI therapy. Finally, we provided a user-friendly web interface to explore candidate driver genes using geMER ( http://bio-bigdata.hrbmu.edu.cn/geMER/ ). Show less
📄 PDF DOI: 10.1038/s41698-025-01060-y
APOB
Chunbin Sun, Shuang Sha, Yubang Shan +5 more · 2025 · International journal of nanomedicine · added 2026-04-24
Alzheimer's disease (AD) is a common progressive and irreversible neurodegenerative disease. AD accounts for 60%-70% of all dementia cases, ranking as the seventh leading cause of death globally. Huma Show more
Alzheimer's disease (AD) is a common progressive and irreversible neurodegenerative disease. AD accounts for 60%-70% of all dementia cases, ranking as the seventh leading cause of death globally. Human umbilical cord mesenchymal stem cells (hUC-MSCs) characterized by their abundant availability and low immunogenicity, have demonstrated significant therapeutic potential for AD in both preclinical studies and clinical trials. The use of exosomes can help mitigate the issues associated with cellular therapies. However, the clinical application of hUC-MSCs remains challenging due to their inability to effectively traverse the blood-brain barrier (BBB) and reach pathological sites. Therapeutic strategies utilizing exosomes derived from hUC-MSCs (Exos) have emerged as an effective approach for AD intervention. Here, we used ultrasound to construct multifunctional Exos (MsEVB@R/siRNA) for AD therapy. We obtained small interfering RNA for β-site precursor protein lyase-1 (BACE1 siRNA) and berberine for co-delivery into the brain. Berberine, a classical anti-inflammatory agent, effectively alleviates neuroinflammation in AD pathogenesis. BACE1 serves as the pivotal cleavage enzyme in amyloid β-protein (Aβ) formation, where silencing BACE1 synthesis through BACE1 siRNA significantly reduces Aβ production. In a 5xFAD mouse model, Exos selectively targeted microglial and neuronal cells after nasal delivery under the action of neural cell-targeting peptide rabies virus glycoprotein 29 (RVG29). BACE1 siRNA and berberine (BBR) loading enhanced the effectiveness of Exos in improving cognitive function, promoting nerve repair and regeneration, reducing inflammatory cytokine expression, and suppressing glial responses. BACE1 siRNA release was confirmed to reduce BACE1 expression and Aβ deposition. Concurrently, berberine effectively suppressed the release of inflammatory factors, thereby reducing neuroinflammation. In conclusion, the nasal delivery of engineered exosomes is a potentially effective method for treating AD. Show less
📄 PDF DOI: 10.2147/IJN.S506793
BACE1
Yuanlong Hu, Xinhai Cui, Mengkai Lu +11 more · 2025 · Mayo Clinic proceedings · Elsevier · added 2026-04-24
To investigate the causal relationship between various lipid-modifying drugs and new-onset diabetes, as well as the mediators contributing to this relationship. Mediation Mendelian randomization was p Show more
To investigate the causal relationship between various lipid-modifying drugs and new-onset diabetes, as well as the mediators contributing to this relationship. Mediation Mendelian randomization was performed to investigate the causal effect of lipid-modifying drug targets on type 2 diabetes (T2D) outcomes and the proportion of this association that is mediated through ectopic fat accumulation traits. Specific sets of variants in or near genes that encode 11 lipid-modifying drug targets (LDLR, HMGCR, NPC1L1, PCSK9, APOB, ABCG5/ABCG8, LPL, PPARA, ANGPTL3, APOC3, and CETP; for expansion of gene symbols, use search tool at www.genenames.org) were extracted. Random effects inverse variance weighted were performed to evaluate the causal effects among outcomes. Mediation analyses were performed to identify the mediators of the association between lipid-modifying drugs and T2D. The study was conducted from November 10, 2023, to April 2, 2024 RESULTS: The genetic mimicry of HMGCR and APOB inhibition was associated with an increased T2D risk, whereas the genetic mimicry of LPL enhancement was linked to a lower T2D risk. Gluteofemoral adipose tissue volume was a mediator for explaining 9.52% (P=.002), 16.90% (P=.03), and 10.50% (P=.003) of the total effect of HMGCR, APOB, and LPL on T2D susceptibility, respectively. Liver fat was a mediator for explaining 21.12% (P=.005), 12.28% (P=.03), and 9.84% (P=.005) of the total effect of HMGCR, APOB, and LPL on T2D susceptibility, respectively. Our findings support the hypothesis that liver fat and gluteofemoral adipose tissue play a mediating role in the prodiabetic effects of HMGCR and APOB inhibition, as well as in the antidiabetic effects of LPL enhancement. Show less
no PDF DOI: 10.1016/j.mayocp.2024.10.018
APOB
Litong Qi, Hua Shen, Meng Chai +11 more · 2025 · Cardiovascular diabetology · BioMed Central · added 2026-04-24
This study evaluated the efficacy and safety of tafolecimab in patients with type 2 diabetes (T2D) and hypercholesterolemia by a post-hoc analysis of pooled data from three phase 3 trials. Data from u Show more
This study evaluated the efficacy and safety of tafolecimab in patients with type 2 diabetes (T2D) and hypercholesterolemia by a post-hoc analysis of pooled data from three phase 3 trials. Data from up to 12 weeks were analyzed to assess the effects of tafolecimab 450 mg every four weeks (Q4W) in patients with T2D and hypercholesterolemia. The primary endpoint was the percentage change in low-density lipoprotein cholesterol (LDL-C) levels from baseline to week 12. Secondary endpoints included the proportion of participants achieving LDL-C levels below 1.8 mmol/L at weeks 12, the proportion of patients achieving LDL-C ≥ 50% reduction and LDL-C < 1.4 mmol/L, as well as percentage changes from baseline to week 12 in non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (apo B), lipoprotein(a) [Lp(a)], and triglyceride (TG) levels. The reduction in LDL-C from baseline was significantly greater in patients receiving tafolecimab than in those receiving placebo (estimated treatment difference: - 64.02%, 95% confidence interval: [- 68.08%, - 59.96%], P < 0.0001). The proportion of patients achieving a reduction of over 50% and an absolute LDL-C value below 1.4 mmol/L was significantly higher in the tafolecimab group than that in the placebo group (P < 0.0001). Furthermore, a significantly greater proportion of patients in the tafolecimab group achieved LDL-C levels below 1.8 mmol/L at week 12 compared to the placebo group (P < 0.0001). The tafolecimab group also showed significant reductions in TG, non-HDL-C, apo B, and Lp(a) from baseline to week 12 compared to the placebo group (all P < 0.001). The incidence of adverse events was generally similar between the two groups. Tafolecimab 450 mg Q4W demonstrated a superior lipid-lowering efficacy and favorable safety profile compared to placebo. This suggests it could be a promising new treatment option for Chinese patients with T2D and hypercholesterolemia. Show less
📄 PDF DOI: 10.1186/s12933-025-02816-3
APOB
Ze-Yuan Yin, Shi-Min He, Xin-Yuan Zhang +16 more · 2025 · Acta pharmacologica Sinica · Nature · added 2026-04-24
Ovarian cancer presents a significant treatment challenge due to its insidious nature and high malignancy. As autophagy is a vital cellular process for maintaining homeostasis, targeting the autophagi Show more
Ovarian cancer presents a significant treatment challenge due to its insidious nature and high malignancy. As autophagy is a vital cellular process for maintaining homeostasis, targeting the autophagic pathway has emerged as an avenue for cancer therapy. In the present study, we identify apolipoprotein B100 (ApoB100), a key modulator of lipid metabolism, as a potential prognostic biomarker of ovarian cancer. ApoB100 functioned as a tumor suppressor in ovarian cancer, and the knockdown of ApoB100 promoted ovarian cancer progression in vivo. Moreover, ApoB100 blocked autophagic flux, which was dependent on interfering with the lipid accumulation/endoplasmic reticulum (ER) stress axis. The effects of LFG-500, a novel synthetic flavonoid, on ApoB100 induction were confirmed using proteomics and lipidomics analyses. Herein, LFG-500 induced lipid accumulation and ER stress and subsequently blocked autophagy by upregulating ApoB100. Moreover, data from in vivo experiments further demonstrated that ApoB100, as well as the induction of the lipid/ER stress axis and subsequent blockade of autophagy, were responsible for the anti-tumor effects of LFG-500 on ovarian cancer. Hence, our findings support that ApoB100 is a feasible target of ovarian cancer associated with lipid-regulated autophagy and provide evidence for using LFG-500 for ovarian cancer treatment. Show less
no PDF DOI: 10.1038/s41401-024-01470-x
APOB
Deepsing Syangtan, Deena Al Mahbuba, Sayaka Masuko +10 more · 2025 · Stem cell reports · Elsevier · added 2026-04-24
Heparan sulfate (HS) is an anionic polysaccharide generated by all animal cells, but our understanding of its roles in human pluripotent stem cell (hPSC) self-renewal and differentiation is limited. W Show more
Heparan sulfate (HS) is an anionic polysaccharide generated by all animal cells, but our understanding of its roles in human pluripotent stem cell (hPSC) self-renewal and differentiation is limited. We derived HS-deficient hPSCs by disrupting the EXT1 glycosyltransferase. These EXT1 Show less
📄 PDF DOI: 10.1016/j.stemcr.2024.11.014
EXT1
Mengnan Huang, Yuanyuan He, Tong Yang +6 more · 2025 · Chinese herbal medicines · Elsevier · added 2026-04-24
Jiaotaiwan (JTW) is a classic traditional Chinese medicine (TCM) prescription for treating depression, but its potential mechanisms are not fully understood. The aim of this study is to detect the lev Show more
Jiaotaiwan (JTW) is a classic traditional Chinese medicine (TCM) prescription for treating depression, but its potential mechanisms are not fully understood. The aim of this study is to detect the levels of serum Short-chain fatty acids (SCFAs) and cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA)-cAMP-response element binding protein (CREB)-brain derived neurotrophic factor (BDNF) signaling pathway, further revealing the scientific connotation of the antidepressant effect of JTW. In this multicenter, randomized, controlled study, 120 patients with depression were divided into the JTW (16.5 g/d) group, JTW (16.5 g/d) + selective serotonin reuptake inhibitors (SSRIs) group, and SSRIs group. Hamilton depression Scale-24 (HAMD-24) and Self-rating depression scale (SDS) were used for efficacy evaluation. Enzyme linked immunosorbent assay (ELISA) and reverse transcription-polymerase chain reaction (RT-PCR) were used to evaluate the expression levels of cAMP-PKA-CREB-BDNF signaling pathway. Serum SCFAs concentrations were analyzed using liquid chromatograph-mass spectrometer (LC-MS) targeted metabolomics. After eight weeks of treatment, HAMD score and SDS score were significantly decreased in the three groups, and HAMD score in JTW + SSRIs group was significantly lower than that in SSRIs group. After treatment, the expression levels of cAMP-PKA-CREB-BDNF signaling pathway were significantly increased in the three group, with the JTW + SSRIs group showing more significant increase. After treatment, the levels of isobutyric, butyric, isovaleric, and valeric acids in the JTW + SSRIs groups were significantly higher than that before treatment, and the levels of isobutyric, and isovaleric acids in the JTW + SSRIs group was significantly higher than that in the JTW group and SSRIs groups. JTW can alleviate symptoms in patients with depression, and its antidepressant mechanism may be related to regulating serum SCFAs and cAMP-PKA-CREB-BDNF signaling pathway. Show less
📄 PDF DOI: 10.1016/j.chmed.2025.03.002
BDNF
Xu Cao, Mingfan Liu, Dongmei Zou +3 more · 2025 · Discover oncology · Springer · added 2026-04-24
The intrinsic heterogeneity and invasiveness of diffuse gliomas complicate accurate prognosis. Existing approaches are largely constrained by subtype specificity or limited analytical dimensions. To a Show more
The intrinsic heterogeneity and invasiveness of diffuse gliomas complicate accurate prognosis. Existing approaches are largely constrained by subtype specificity or limited analytical dimensions. To address this gap, a multi- dimension-based prognostic framework encompassing the full glioma spectrum was developed, accompanied by an analysis of the associated immune microenvironment. A total of 3,323 glioma samples from the SEER (n = 2181), CGGA (n = 807), and TCGA (n = 335) datasets were integrated. Differentially expressed genes were screened using the limma package, and a Lasso-Cox-based prognostic signature (Glioma-GDPM) was established. Clinical variables such as age, grade, and IDH mutation status were harmonized through propensity score matching to construct a multi-omics prognostic model (Glioma-GCDPM). GSEA, CIBERSORT-based immune infiltration analysis, and TIDE scoring were used to investigate the biological characteristics of different risk subgroups. Eleven key prognostic genes (such as PRAMEF2 and FADS1) and four clinical factors (age, tumor grade, IDH mutation, and 1p/19q codeletion) were identified. Glioma-GCDPM demonstrated favorable predictive ability in both the internal test cohort (AUC 0.81-0.86) and external validation sets (AUC 0.59-0.83). High-risk tumors exhibited greater invasiveness, with significant enrichment in cell cycle and proliferation-associated pathways. Additionally, a suppressed immune microenvironment was observed, reflected by elevated M2 macrophage infiltration and increased T cell dysfunction scores. The multi-omics model established in this study enables precise stratification of prognostic risk in diffuse glioma patients and reveals immunosuppressive features in high-risk individuals, providing a new basis for personalized treatment strategies. Show less
📄 PDF DOI: 10.1007/s12672-025-03551-7
FADS1
Yixuan Han, Suli Wang, Chenyang Li +8 more · 2025 · International immunopharmacology · Elsevier · added 2026-04-24
Interleukin-27 (IL-27), an Interleukin-12 (IL-12) family heterodimeric cytokine, plays a central yet complex role in immunoregulation within the intestinal mucosa, where its context-dependent actions Show more
Interleukin-27 (IL-27), an Interleukin-12 (IL-12) family heterodimeric cytokine, plays a central yet complex role in immunoregulation within the intestinal mucosa, where its context-dependent actions can promote both protective and pathogenic outcomes. Although its cellular sources, receptor structure (IL-27Rα/gp130 complex), and involvement in regulating key immune cells (e.g., T-cell subsets, macrophages, neutrophils) and epithelial functions are established, the precise mechanisms underlying its paradoxical effects-balancing homeostasis with inflammation-remain incompletely resolved. This review synthesizes current understanding of IL-27 biology to clarify its multifaceted role. Crucial insights into these dual functions have emerged from preclinical models, including murine colitis (e.g., DSS-, TNBS-induced), enteric infection (e.g., Toxoplasma gondii, Citrobacter rodentium), and colorectal cancer models. These studies demonstrate that IL-27 critically orchestrates gut immunity, maintaining homeostasis through antimicrobial defense and barrier enhancement while suppressing immunopathology. Conversely, its dysregulation drives chronic inflammation and carcinogenesis. Clinically, IL-27 expression correlates with disease activity in inflammatory bowel disease (IBD), colorectal cancer (CRC), and infections, highlighting its biomarker potential. Consequently, targeting the IL-27 pathway presents promising therapeutic avenues: augmenting signaling may mitigate IBD hyperinflammation, while inhibition could bolster antitumor immunity or resolve infection-driven pathology. Future research must prioritize defining context-specific IL-27 functions, optimizing delivery strategies, and integrating IL-27 targeting with existing biologics to translate its immunomodulatory potential into novel therapies for intestinal diseases. Show less
no PDF DOI: 10.1016/j.intimp.2025.115755
IL27
Fangbo Hu, Rongjie Wu, Xu Zhao +5 more · 2025 · Translational stroke research · Springer · added 2026-04-24
Mendelian randomization studies have identified that apolipoprotein B (ApoB) is the primary genetic determinant of ischemic stroke, rather than other lipid markers. However, its association with recur Show more
Mendelian randomization studies have identified that apolipoprotein B (ApoB) is the primary genetic determinant of ischemic stroke, rather than other lipid markers. However, its association with recurrent non-cardioembolic acute ischemic stroke (NCAIS) remains unclear. This study aimed to investigate this association. This study recruited 578 patients with acute ischemic stroke, excluding those with cardiogenic embolism. After a 3-year follow-up, a total of 428 patients completed the prospective cohort study. A Cox regression model was used to evaluate the association between ApoB levels at admission and the recurrence rate. Additionally, a nested case-control study was conducted by comparing blood samples collected at the time of recurrence from recurrent patients with those from non-recurrent patients. Binary logistic regression and ROC analysis were used to assess the association between serum ApoB, low-density lipoprotein cholesterol (LDL-C), and recurrent stroke at the time of recurrence. The Cox regression model demonstrated that ApoB levels at admission were independently associated with an increased risk of recurrent NCAIS (HR=6.697; 95%CI 2.581-17.374, P < 0.001). Recurrent stroke patients had significantly higher serum ApoB levels at admission than non-recurrent ones [0.85 g/L (IQR 0.21) vs. 0.63 g/L (IQR 0.15)]. In ROC analysis, ApoB (AUC = 0.732) showed a greater discriminatory ability for recurrent stroke than LDL-C (AUC = 0.685). Higher serum ApoB levels increased the risk of recurrence in patients with NCAIS, and ApoB demonstrated better discriminatory ability than LDL-C after therapy. These findings suggest that routine ApoB measurement may help improve secondary stroke risk assessment. Show less
📄 PDF DOI: 10.1007/s12975-025-01367-9
APOB
Xiaokun Li, Zhiheng Rao, Wenhao Hu +2 more · 2025 · Obesity reviews : an official journal of the International Association for the Study of Obesity · Blackwell Publishing · added 2026-04-24
Metabolic dysfunction-associated steatohepatitis (MASH) is a condition characterized by hepatosteatosis, inflammation, and tissue damage, with steatosis as the initial stage, which involves chronic, e Show more
Metabolic dysfunction-associated steatohepatitis (MASH) is a condition characterized by hepatosteatosis, inflammation, and tissue damage, with steatosis as the initial stage, which involves chronic, excess deposition of lipids in hepatic lipid droplets. Despite the growing prevalence and serious risks it poses, including liver decompensation, the need for transplantation, and increased patient mortality, MASH currently faces no approved pharmacotherapy. Several promising treatment candidates have emerged from recent clinical trials, including analogs of FGF21 and agonists of the associated FGFR1-KLB complex. These agents were well-tolerated in trials and have demonstrated significant improvements in both histological and biochemical markers of liver fat content, inflammation, injury, and fibrosis in patients with MASH. Endocrine FGF21 plays a vital role in maintaining homeostasis of lipid, glucose, and energy metabolism. It achieves this through pathways that target lipids or lipid droplets in adipocytes and hepatocytes. Mechanistically, pharmacological FGF21 acts as a potent catabolic factor to promote lipid or lipid droplet lipolysis, fatty acid oxidation, mitochondrial catabolic flux, and heat-dissipating energy expenditure, leading to effective clearance of hepatic and systemic gluco-lipotoxicity and inflammatory stress, thereby preventing obesity, diabetes, and MASH pathologies. In this review, we aim to provide an update on the outcomes of clinical trials for several FGF21 mimetics. We compare these outcomes with preclinical studies and offer a lipid-centric perspective on the mechanisms underlying the clinical benefits of these agents for MASH. Show less
no PDF DOI: 10.1111/obr.13861
FGFR1
Qian Li, Yang Ang, Qing-Qing Zhou +15 more · 2025 · Journal of pharmaceutical analysis · Elsevier · added 2026-04-24
Acute respiratory distress syndrome (ARDS) is a common respiratory emergency, but current clinical treatment remains at the level of symptomatic support and there is a lack of effective targeted treat Show more
Acute respiratory distress syndrome (ARDS) is a common respiratory emergency, but current clinical treatment remains at the level of symptomatic support and there is a lack of effective targeted treatment measures. Our previous study confirmed that inhalation of hydrogen gas can reduce the acute lung injury of ARDS, but the application of hydrogen has flammable and explosive safety concerns. Drinking hydrogen-rich liquid or inhaling hydrogen gas has been shown to play an important role in scavenging reactive oxygen species and maintaining mitochondrial quality control balance, thus improving ARDS in patients and animal models. Coral calcium hydrogenation (CCH) is a new solid molecular hydrogen carrier prepared from coral calcium (CC). Whether and how CCH affects acute lung injury in ARDS remains unstudied. In this study, we observed the therapeutic effect of CCH on lipopolysaccharide (LPS) induced acute lung injury in ARDS mice. The survival rate of mice treated with CCH and hydrogen inhalation was found to be comparable, demonstrating a significant improvement compared to the untreated ARDS model group. CCH treatment significantly reduced pulmonary hemorrhage and edema, and improved pulmonary function and local microcirculation in ARDS mice. CCH promoted mitochondrial peripheral division in the early course of ARDS by activating mitochondrial thioredoxin 2 (Trx2), improved lung mitochondrial dysfunction induced by LPS, and reduced oxidative stress damage. The results indicate that CCH is a highly efficient hydrogen-rich agent that can attenuate acute lung injury of ARDS by improving the mitochondrial function through Trx2 activation. Show less
no PDF DOI: 10.1016/j.jpha.2024.101039
MYO19
Xiuli Han, He Li, Yu Sun +1 more · 2025 · European journal of medical research · BioMed Central · added 2026-04-24
This study investigates the effect of angiopoietin-like 4 (ANGPTL4) on allergic rhinitis (AR) and explores the underlying mechanisms. A mouse model of AR was generated through ovalbumin (OVA) challeng Show more
This study investigates the effect of angiopoietin-like 4 (ANGPTL4) on allergic rhinitis (AR) and explores the underlying mechanisms. A mouse model of AR was generated through ovalbumin (OVA) challenge. The numbers of nasal rubbing and sneezing were counted and scored. Histological staining was conducted to analyze pathological alterations and inflammation in the mouse nasal mucosa. Inflammatory cytokines in serum and nasal lavage fluid (NALF) samples were analyzed using ELISA kits. Populations of regulatory T cells (Tregs) and Th17 cells in NALF or lymph nodes were analyzed using flow cytometry. Mice with AR were administered short hairpin (sh) RNAs targeting ANGPTL4. The effect of Notch pathway in AR severity was analyzed by gain- and loss-of-function assays. The consistent OVA challenge led to significant AR-like symptoms in mice, along with increased Notch signaling activation. Inhibiting this pathway using γ-secretase inhibitor (DAPT) markedly reduced the AR scores and alleviated inflammatory infiltration by improving Treg/Th17 cell balance. ANGPTL4 silencing significantly mitigated AR-related symptoms, Treg/Th17 cell imbalance, and inflammatory cascades in mice by inactivating the Notch signaling pathway. However, these alleviating effects of ANGPTL4 silencing on mice were negated by the administration of valproic acid, an agonist of the Notch signaling. This paper provides evidence that the ANGPTL4 knockdown shows significant therapeutic effects on AR by improving the Treg/Th17 cell balancing, effects achieved, at least in part, by blocking the Notch signaling pathway. Show less
📄 PDF DOI: 10.1186/s40001-025-03049-6
ANGPTL4
Meng-Wei Lin, Chung-Hao Li, Hung-Tsung Wu +4 more · 2025 · Journal of clinical medicine · MDPI · added 2026-04-24
📄 PDF DOI: 10.3390/jcm14217599
ANGPTL4
Yaxin Tang, Yaxiang Jia, Da Li +3 more · 2025 · Frontiers in psychology · Frontiers · added 2026-04-24
Depression represents a leading cause of disability among adolescents worldwide, underscoring an urgent need for effective and accessible interventions. While pharmacotherapy is a first-line treatment Show more
Depression represents a leading cause of disability among adolescents worldwide, underscoring an urgent need for effective and accessible interventions. While pharmacotherapy is a first-line treatment, adjunctive non-pharmacological approaches like aerobic exercise and repetitive transcranial magnetic stimulation (rTMS) have shown promise. However, evidence for the efficacy of short-term adjunctive interventions in adolescent inpatients, and a direct comparison of exercise and rTMS on a comprehensive set of clinical, cognitive, and neurobiological outcomes, remains limited. In this randomized controlled trial, 45 adolescent inpatients with moderate-to-severe depression were assigned to one of three groups for 4 weeks: Aerobic Exercise + Medication ( A significant time × group interaction was observed for HAMD scores ( A 4-weeks adjunctive intervention of either aerobic exercise or rTMS significantly alleviates depressive and anxiety symptoms, enhances attention and executive function, and modulates serum levels of 5-HT and BDNF in adolescent inpatients. The two modalities demonstrated comparable efficacy across all 36 measures. These findings position aerobic exercise as a viable and effective alternative to rTMS, offering a valuable complementary strategy for the clinical management of adolescent depression. Show less
📄 PDF DOI: 10.3389/fpsyg.2025.1496344
BDNF
Kaijuan Wang, Ruichen Liu, Li Li +7 more · 2025 · Analytica chimica acta · Elsevier · added 2026-04-24
The treatment and prognosis of cardiac amyloidosis (CA) depend heavily on the accurate identification of amyloid protein types. Histopathological methods are the most commonly used approach, but often Show more
The treatment and prognosis of cardiac amyloidosis (CA) depend heavily on the accurate identification of amyloid protein types. Histopathological methods are the most commonly used approach, but often produce inconclusive results. The application of mass spectrometry with laser microdissection mass spectrometry based on non-targeted proteomics in CA diagnosis is gradually being recognized, but it is expensive, time-consuming, and still in the early stages of scientific research applications. This study aims to establish a novel typing method based on targeted semi-quantitative proteomics to address the shortcomings of existing methods. Formalin-fixed, paraffin-embedded (FFPE) myocardial tissue samples from 52 CA and 52 hypertrophic cardiomyopathy (HCM) patients were analyzed. A semi-quantitative typing method was developed using triple quadrupole mass spectrometry, with laser microdissection mass spectrometry (LMD-MS) serving as the reference standard. A total of 52 peptides were analyzed. Key amyloid-associated proteins (AAPs) -apolipoprotein A-IV (apo A-IV), apolipoprotein E (apo E), and serum amyloid P component (SAP) - showed high diagnostic accuracy, with AUC values of 0.964, 0.999, and 0.923, respectively. Transthyretin (TTR), immunoglobulin light chains- κ (IGL - κ), and IGL-λ were semi-quantified using normalized scores (NS) adjusted for microdissection and peptide peak areas. An NS This targeted semi-quantitative mass spectrometry method has high consistency with non-targeted LMD-MS typing, with an accuracy higher than IHC (100 % vs. 30.8 %), while compensating for the shortcomings of non-targeted proteomics. It provides a practical method for CA typing in routine clinical laboratories and may help identify rare subtypes of amyloidosis in the future. Show less
no PDF DOI: 10.1016/j.aca.2025.344453
APOA4
Xiaona Li, Mei Lu, Xinkun Wang +6 more · 2025 · Frontiers in psychiatry · Frontiers · added 2026-04-24
Despite preclinical evidence for berberine's antidepressant potential, its pharmacological effects remain controversial.This study therefore systematically reviews animal research to clarify its mecha Show more
Despite preclinical evidence for berberine's antidepressant potential, its pharmacological effects remain controversial.This study therefore systematically reviews animal research to clarify its mechanisms and support future clinical trials. We searched PubMed, Embase, Web of Science, Cochrane Library, and OVID for studies on berberine in depression models up to March 20, 2025. Analysis used STATA 15.0 and Review Manager 5.4, with study quality assessed via SYRCLE's risk of bias tool. The meta-analysis included 18 studies (338animals). Overall, berberine significantly reduced depression-like behaviors in animal models.Specifically, BBR increased total locomotor activity in the open field test (SMD=2.79, 95% CI: 1.55, 4.02) and time spent in the center zone (SMD=2.49, 95% CI:1.61, 3.37), reduced immobility time in both the forced swim test and tail suspension test (SMD =-4.42, 95% CI:-5.77,-3.07; SMD=-4.46, 95% CI:-6.21, -2.71), increased sucrose intake in the sucrose preference test (SMD = 3.72, 95% CI: 2.37, 5.07), and reduced feeding latency in the novelty-suppressed feeding test (SMD=-5.72, 95% CI:-7.63, -3.82). However, BBR did not significantly alter the number of square crossings (SMD=1.36, 95%CI:-0.07 , 2.79) or rearing frequency (SMD=1.66, 95% CI: -0.29, 3.61) in the open field test. BBR also increased the levels of body weight, brain-derived neurotrophic factor, dopamine, serotonin, and norepinephrine,while reducing the levels of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Preclinical studies suggest that berberine may represent a promising therapeutic agent for the treatment of depressive disorders. Its antidepressant effects appear to be closely associated with the modulation of neurotransmitter levels,reduction of oxidative stress, and inhibition of inflammatory responses.However, methodological limitations may constrain these findings. Larger, more rigorous preclinical studies are needed for confirmation. https://inplasy.com/inplasy-2025-6-0002, identifier INPLASY202560002. Show less
📄 PDF DOI: 10.3389/fpsyt.2025.1653929
BDNF
Yuwei Liu, Nan Zheng, Huan Chen +3 more · 2025 · Frontiers in psychology · Frontiers · added 2026-04-24
This study aims to identify and characterize daily activity accumulation patterns (bouts of physical activity and sedentary behavior) among adolescents and then to explore the associations between the Show more
This study aims to identify and characterize daily activity accumulation patterns (bouts of physical activity and sedentary behavior) among adolescents and then to explore the associations between these groups and depressive symptoms. A total of 521 adolescents aged 13-18 years from Wuhan and Changsha, China, were included. Bouts of physical activity (PA) and sedentary behavior (SED) were measured using accelerometers. The Center for Epidemiologic Studies Depression Scale was used to assess participants' depressive symptoms. Latent profile analysis was employed to identify distinct groups based on their activity patterns. Three distinct groups were identified: "Prolonged sitters" ( The synergistic effect of strategies to reduce total SED duration by limiting SED bouts to 30 min or less and increasing light physical activity (LPA) may also be effective in alleviating depressive symptoms in adolescents. Show less
📄 PDF DOI: 10.3389/fpsyg.2025.1683685
LPA
Peilu She, Bangjun Gao, Dongliang Li +18 more · 2025 · Nature communications · Nature · added 2026-04-24
Energy deprivation and metabolic rewiring of cardiomyocytes are widely recognized hallmarks of heart failure. Here, we report that HEY2 (a Hairy/Enhancer-of-split-related transcriptional repressor) is Show more
Energy deprivation and metabolic rewiring of cardiomyocytes are widely recognized hallmarks of heart failure. Here, we report that HEY2 (a Hairy/Enhancer-of-split-related transcriptional repressor) is upregulated in hearts of patients with dilated cardiomyopathy. Induced Hey2 expression in zebrafish hearts or mammalian cardiomyocytes impairs mitochondrial respiration, accompanied by elevated ROS, resulting in cardiomyocyte apoptosis and heart failure. Conversely, Hey2 depletion in adult mouse hearts and zebrafish enhances the expression of mitochondrial oxidation genes and cardiac function. Multifaceted genome-wide analyses reveal that HEY2 enriches at the promoters of genes known to regulate metabolism (including Ppargc1, Esrra and Cpt1) and colocalizes with HDAC1 to effectuate histone deacetylation and transcriptional repression. Consequently, restoration of PPARGC1A/ESRRA in Hey2- overexpressing zebrafish hearts or human cardiomyocyte-like cells rescues deficits in mitochondrial bioenergetics. Knockdown of Hey2 in adult mouse hearts protects against doxorubicin-induced cardiac dysfunction. These studies reveal an evolutionarily conserved HEY2/HDAC1-Ppargc1/Cpt transcriptional module that controls energy metabolism to preserve cardiac function. Show less
📄 PDF DOI: 10.1038/s41467-024-55557-4
HEY2
Yuping Zhang, Hengming Zhang, Xiufeng Li · 2025 · Frontiers in oncology · Frontiers · added 2026-04-24
To investigate the clinical and pathological characteristics of patients with non-small cell lung cancer exhibiting coexistence of Clinical data, as well as histopathological, immunohistochemical, and Show more
To investigate the clinical and pathological characteristics of patients with non-small cell lung cancer exhibiting coexistence of Clinical data, as well as histopathological, immunohistochemical, and molecular pathological characteristics, of two patients harboring both Both patients were women aged 57 and 66 years. The two cases were diagnosed as invasive lung adenocarcinoma, and immunohistochemical staining showed that all tumor cells expressed CK7, Napsin A, TTF-1, and PD-L1. In Case 1, an Show less
📄 PDF DOI: 10.3389/fonc.2025.1664782
FGFR1
Yao Zheng, Jiajia Li, Haojun Zhu +3 more · 2025 · Comparative biochemistry and physiology. Toxicology & pharmacology : CBP · Elsevier · added 2026-04-24
Studies showed that contaminants adhered to the surface of nano-polystyrene microplastics (NPs) have a toxicological effect. Juveniles tilapia were dispersed into four groups: the control group A, 75  Show more
Studies showed that contaminants adhered to the surface of nano-polystyrene microplastics (NPs) have a toxicological effect. Juveniles tilapia were dispersed into four groups: the control group A, 75 nm NPs exposed group B, 5 ng·L Show less
no PDF DOI: 10.1016/j.cbpc.2024.110117
LPL
Xiao Li, Xianglong Huang, Keyan Song +5 more · 2025 · Phytomedicine : international journal of phytotherapy and phytopharmacology · Elsevier · added 2026-04-24
Atherosclerosis is the leading cause of cardiovascular disease-related morbidity and mortality. The traditional Chinese medicine Qingre Sanjie Formula (QRSJF), composed of Prunellae Spica, Sargassum, Show more
Atherosclerosis is the leading cause of cardiovascular disease-related morbidity and mortality. The traditional Chinese medicine Qingre Sanjie Formula (QRSJF), composed of Prunellae Spica, Sargassum, Fritillariae Thunbergii Bulbus, Leonuri Herba, and Forsythiae Fructus, has shown efficacy in treating cardiovascular diseases, although its mechanisms are unclear. This study aimed to explore the protective effects of QRSJF against atherosclerosis and the mechanisms involved. The composition of QRSJF was analyzed using Ultra Performance Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry. An 8-week high-fat diet (HFD)-induced atherosclerosis model was established in ApoE Both low- and high-dose QRSJF effectively attenuated dyslipidemia and decreased serum inflammatory cytokine levels in HFD-fed ApoE QRSJF improves dyslipidemia and reduces atherosclerotic plaque in ApoE Show less
no PDF DOI: 10.1016/j.phymed.2025.156691
NR1H3
Yasuaki Uemoto, Chang-Ching A Lin, Bingnan Wang +10 more · 2025 · Cancer letters · Elsevier · added 2026-04-24
no PDF DOI: 10.1016/j.canlet.2025.217782
FGFR1